Royalty Report: Wound Care, Medical, Supply – Collection: 304408

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Wound Care
  • Medical
  • Supply
  • Drugs
  • Therapeutic
  • Surgical
  • Pharmaceuticals
  • Skin care
  • Antimicrobial
  • cell therapy
  • Tissue
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 304408

License Grant
The Company has an exclusive sublicense to distribute CellerateRX® Activated Collagen® products into the wound care and surgical markets in the United States, Canada and Mexico.
License Property
CellerateRX® is a wound and skin care product for use by surgeons on surgical wounds consisting of a Surgical Powder that is a medical hydrolysate of Type I bovine collagen.  When applied to a surgical wound, the hydrolyzed collagen is ready to aid in the natural wound healing process.

Licensor manufactures the products and owns the CellerateRX registered trademark.

Field of Use
CellerateRX Surgical Powder is a medical hydrolysate of Type I bovine collagen indicated for the management of
Surgical wounds
Traumatic wounds
Partial- and full-thickness wounds
First- and second-degree burns

Licensee will utilize the wound and skin care products for external wounds, including the treatment of external, tunneled or undermined wounds.  These products are used by surgeons in the medical industry. This would include pressure ulcers (Stages I-IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second-degree burns, superficial wounds, cuts, scrapes, skin tears, skin flaps and skin grafts.

The Licensees business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 287103

License Grant
The Company consummated definitive agreements that continued operations to market the Company’s principal products, CellerateRX® Surgical Activated Collagen® Peptides and CellerateRX® Hydrolyzed Collagen wound fillers (CellerateRX), through a 50% ownership interest in a newly formed Texas limited liability company,  which began operations on September 1, 2018.

The Companys affiliate conducts operations with an exclusive sublicense from the Licensors affiliate to distribute Licensees products into the wound care and surgical markets in the United States, Canada and Mexico.

License Property
The Companys products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.

CellerateRX® Gel is a hydrolyzed collagen wound dressing (approximately 65% type I collagen).

Field of Use
CellerateRX® products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.

The Company’s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 614

License Grant
The Licensors grants the Licensee a non-revocable, exclusive, sub-licensable, transferable right in and to the Licensed IP to make, have made, use, sell, export, reproduce, market and distribute Products for External Wound Care in the field of use.
License Property
External Wound Care means the treatment of external, tunneled or undermined wounds (including, without limitation, pressure ulcers (Stages I – IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second degree burns, superficial wounds, cuts scrapes, skin tears, skin flaps and skin grafts.

Patent means – United States Patent No. 6,136,341.

The patented technologies and processes related to CellerateRxTM, an advanced collagen based wound care product formulation.  These new licenses are limited to the human health care market for external wound care, and include any new product developments based on the licensed patent and processes.

Field of Use
The Field of Use means the worldwide human health care market, (excluding the veterinary, nutritional and injectable markets as well as all other uses) and subject to certain exceptions.

IPSCIO Record ID: 1396

License Grant
The Licensee entered into separate exclusive license agreements with both Licensor and its founder.

Licensee obtained the exclusive worldwide license to certain patented technologies and processes related to CellerateRX. Licensee had been marketing and selling CellerateRX during the previous four years under the terms of a distribution agreement with Licensor that was terminated in 2005.  The new licenses are limited to the human health care market for external wound care including surgical wounds, and include any new product developments based on the licensed patent and processes and any continuations.

License Property
CellerateRX is a patented collagen wound care product.

CellerateRX has a competitive proprietary feature and performance advantages over other collagen-based products. It is available in powder (95% collagen) and gel (65%) forms that don't need special handling (like refrigeration). It is active in all 4 phases of wound healing.

Field of Use
The new licenses are limited to the human health care market for external wound care including surgical wounds, and include any new product developments based on the licensed patent and processes and any continuations.

IPSCIO Record ID: 282564

License Grant
Licensee executed a license agreement with Licensee (director of Licensee is also a director and significant shareholder of Licensor), whereby Licensee acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body.

Licensee acquired an exclusive world-wide license to market, sell, distribute, and further develop certain antimicrobial barrier film and skin protectant products, utilizing certain Licensor patents and pending patent applications.

License Property
The products covered by the License Agreement are BIAKOSâ„¢ Antimicrobial Barrier Film and a skin protectant product with a registered trademark pending.

BIAKS is an FDA-cleared and patented composition that effectively disrupts extracellular polymeric substances to eradicate biofilm microbes. BIAKS is intended for mechanical removal of debris, dirt, foreign materials, and microorganisms from wounds including stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first and second-degree burns as well as grafted and donor sites. BIAKS is effective in killing free-floating microbes, immature, and mature bacterial biofilms such as MRSA and Pseudomonas aeruginosa, and fungal biofilms such as Candida albicans. In addition, BIAKS safety studies show that it is non-cytotoxic, non-irritating, and non-sensitizing to healthy skin and assists in the normal wound healing process.

8,852,648 Delivery of biologically-active agents using volatile, hydrophobic solvents

8,877,882 Non-self-adherent coating materials

Field of Use
The currently licensed products are BIAKOSâ„¢ Antimicrobial Wound Gel, and FDA cleared BIAKOSâ„¢ Antimicrobial Skin and Wound Cleanser.

BIAKOSâ„¢ Antimicrobial Skin & Wound Cleanser is a patented product that effectively disrupts extracellular polymeric substances to eradicate biofilm microbes. BIAKOS Antimicrobial Skin & Wound Cleanser also provides mechanical removal of debris, dirt, foreign materials, and microorganisms from wounds including stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first and second-degree burns as well as grafted and donor sites. BIAKOS Antimicrobial Skin & Wound Cleanser is effective in killing free-floating microbes, immature, and mature bacterial biofilms such as MRSA and Pseudomonas aeruginosa, and fungal biofilms such as Candida albicans. In addition, BIAKOS Antimicrobial Skin & Wound Cleanser safety studies show that it is non-cytotoxic, non-irritating, and non-sensitizing to healthy skin and assists in the normal wound healing process.

IPSCIO Record ID: 287764

License Grant
Under the terms of this agreement, the Company recognizes royalty revenue on sales of products containing the Companys patented resorbable bone hemostasis.
License Property
The Companys products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.
Field of Use
Licensed refers to certain bone wax rights to Licensee to develop products in the field of bone remodeling, based on Resorbable’s patent number 7,074,425 (see Note 9 “Intangible Assets”) for use in the human skeletal system.

The Company’s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 2596

License Grant
The Company granted an exclusive license to manufacture, distribute, market and sell all of its products in a designated territory to Licensee, Jakarta, Indonesia.
License Property
The Company engages in the development, marketing and sale of primarily proprietary sprays, ointments and dressings for the management of certain chronic non-healing skin ulcerations such as pressure, diabetic and venous ulcers, surgical incisions and burns.
Field of Use
The rights granted apply to chronic wounds and wound care.

IPSCIO Record ID: 356294

License Grant
Licensor grants an exclusive license, with the right to sublicense, under the Licensor Technology, to Develop and Commercialize, including to use, offer for sale and sell Licensed Products in the Field in the Territory.

Licensor grants an exclusive license to use and display, with the right to grant sublicenses to any sublicensees permitted and contract research organizations, distributors and other Third Parties who perform activities directly on behalf of Licensee, provided that such sublicense is incidental to the activities performed by such Third Party, during the Term and in the Field in the Territory, to the Biovance and/or ECM trademark, to identify the Licensed Products.

For Commercialization Outside the Territory, Licensor grants the right of first negotiation, under mutually acceptable terms between the Parties, to enter into an agreement to market and/or sell the Licensed Products, whether on an exclusive or non-exclusive basis in the Field in any jurisdictions outside the Territory.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor owns or has rights to placental based products, including intellectual property relating thereto.

Biovance means decellularized, dehydrated human amniotic membrane, as produced according to the Licensor Technology as of the Effective Date or thereafter, which are marketed under the Biovance name.

ECMs means extracellular matrix derived from the human placenta, as produced according to the Licensor Technology as of the Effective Date or thereafter, which may be, but is not necessarily formulated into sheets, particulates, or a flowable matrix.

Field of Use
Field means acute and chronic non-healing wounds pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunnel/undermined wounds, surgical wounds, donor sites/grafts, dehiscence, trauma wounds, abrasions, lacerations, second degree bums, and skin tears, and draining wounds.

Competing Product means any advanced biologic wound care biological skin substitute product derived from the placenta in the Field, other than a Licensed Product.

IPSCIO Record ID: 27094

License Grant
The Licensee is to pay a royalty derived from the sale, license or other exploitation of the intellectual property of the Licensee to the Founder of the Company.  The Licensee, a development stage enterprise, is in the business of providing proprietary, turnkey solutions to the chronic wound care field through its AuTolo-Cure System developed by the Founder.
License Property
AuTolo(TM)-Gel is a proprietary autologous tissue coagulum for treating chronic non healing wounds such as; diabetic foot ulcers, venous stasis wounds and pressure ulcers.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 27075

License Grant
The Company has the exclusive right to utilize the process to make and apply AuTolo-Gel TM and full and exclusive right, title and interest, both national and international, to certain patent applications identified as the Patent Cooperation Treaty Application entitled Enriched Platelet Wound Healant the Licensor, an individual.
License Property
The AuTolo-Cure TM system is based upon the use of a process developed for the application of an autologous platelet-rich concentrated gel to chronic wounds. The process removes platelets from the individual, applies a process developed by Worden to create AuTolo-Gel TM and then applies the gel to the wound.  By using the patient’s own platelets to create the gel, the system is an autologous process.
Field of Use
The Company intends to market and sell its proprietary system for the treatment of chronic wounds presently identified by the servicemark, AuTolo-Cure TM ('the AuTolo-Cure TM system').   AuTolo(TM)-Gel is a proprietary autologous tissue coagulum for treating chronic nonhealing wounds such as; diabetic foot ulcers, venous stasis wounds and pressure ulcers.

IPSCIO Record ID: 783

License Grant
This Amendment No. 1 is made in full settlement of any rights either party may have to OBIs products Woundecyte â„¢, Dermacyte â„¢, and any other cosmetic or dermatology products which OBI has or will develop which will employ a perfluorocarbon (PFC) gel.  The Licensor shall be deemed to have been a contributor on the development of perfluorocarbon (PFC) gel based products used to treat burns and wounds, whether with our without the use of a bandage or with or without the use of an oxygen generator. This includes Woundecyte â„¢. For purposes of the License Agreement, the PFC gel based products used to treat burns and wounds will be considered Licensed Products, whether or not any patents are obtained on the PFC gel based products used to treat burns and wounds, and OBI will be obligated to pay milestone, sublicensing and royalty payments on the PFC gel based products used to treat burns and wounds.
License Property
1. PCT application, filed May 14, 2007, Publication No. WO2007134304 entitled “Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides” based on VCU invention 06-31

2. Provisional patent application, filed 02/13/2008, Serial No. 61/028230, entitled “Gas Based Wound and Tissue Therapeutics”, based on VCU invention VCU 08-008

3. Provisional patent application, filed 12/10/2007, Serial No. 61/012,508, entitled “Novel Combinatorial Approaches to Enhance Oxygen Transport to Tissues”, based on VCU invention VCU 07-080

Traditional treatment of wounds, such as burns, chronic skin ulcers and the like has relied on ensuring proper intravascular resuscitation to help ensure adequate perfusion of the wounds to maintain levels of oxygen in the wound capable of meeting tissue needs and thus promote survival and healing. When perfusion is severely jeopardized, for example in cases of chronic wounds such as pressure, diabetic, venous stasis and arterial ulcers where the vasculature has been severely damaged over time, the use of hyperbaric oxygen has been advocated as a means to enhance oxygenation. In addition to being bactericidal and static, intermittent use of hyper- oxygenation is believed to be beneficial as it may lead to increased tissue oxygenation and ultimate angiogenesis . Furthermore, increased tissue oxygenation may assist in decreasing the inflammatory response.

IPSCIO Record ID: 299291

License Grant
Licensor grants Licensee of the Cayman Islands an exclusive license under the Licensed Patents and Licensed Technology in both cases to make, have made, use, sell, offer to sell, import, and otherwise distribute and dispose of Products in each case solely in the Field throughout the Territory.

Licensor grants a non-exclusive license to use the Licensor Marks solely in connection with the marketing, promotion and sale of the Product(s) in the Field.

License Property
Licensor is the sole owner of Patent entitled Use of physiologically balanced, ionized, acidic solution in wound healing.

Product shall mean any product comprising any formulation containing hypochlorous acid as its principal active ingredient including that product known as NVC-101.

NVC-101 is a topical antimicrobial that can decrease the bacterial bioburden of chronic wounds.

Field of Use
The Field shall mean, with respect to Products, all commercial uses of the Products for wound care, wound healing, wound cleaning, wound debridement, wound disinfection, wound inflammation, wound exudate management, wound granulation, wound reepithelialization and any other form of wound treatment or wound management including use in surgical wounds and associated disinfection as well as any other treatments that may be adapted to be assisted by reduced pressure, all in humans, but shall exclude for all purposes any products or uses intended for the eye, ear or nose, including the prevention or treatment of any infection thereof.

IPSCIO Record ID: 353934

License Grant
Licensed Patents License Licensor hereby grants to Licensee during the Term a nontransferable, nonsublicensable, exclusive right and license under the Licensed Patents in the Field of Use to make, use, offer to sell, sell, and import Licensed Products in the Territory.

Know-How License Licensor hereby grants to Licensee during the Term a nontransferable, nonsublicensable, exclusive right and license in the Field of Use under the Licensed Know-How to make, use, offer to sell, sell, and import Licensed Products.

Licensee hereby grants to Licensor a non-exclusive, nonsublicensable, nontransferable, worldwide, royalty-free, license to all Improvements for use by Licensor to make, use, sell, offer for sale and/or import Licensors products solely outside the Field of Use.

License Property
US Patent Applications
1 – METHODS OF DECELLULARIZING BONE Utility – NPREG
United States of America
Issued
13/787,625
2 – U.S. Provisional Patent Application entitled FISTULA FILLER AND DEPLOYMENT SYSTEM, Application No. 62/684,426; Filing Date June 13, 2018, U.S. PROVISIONAL CONVERSION/ PARIS CONVENTION DEADLINE JUNE 13, 2019
3 – U.S. Provisional Patent Application entitled IMPROVED DECELLULARIZATION OF ISOLATED ORGANS, Application No. 62/821,620
4 – U.S. Provisional Patent Application entitled NON-DESTRUCTIVE METHOD OF DEHYDRATION OF EXTRACELLULAR MATRIX OF DECELLULARIZED ORGANS AND PARTICLES FORMED THEREFROM, Application No. 62/789,218

Miromeshâ„¢ and MirodermTM products
and the following products in development or previously considered
Tendon Wrap
Wound Particulate
Nerve Wrap
Void Filler
Fistula

Miromesh is a biological mesh made using perfusion decelluarized porcine liver for hernia repair applications. It is designed to be implanted to boost soft tissue.

MiroDerm® is a non-crosslinked acellular wound matrix, derived from the highly vascularized porcine liver. It is intended for the management of wounds, including partial and full-thickness wounds; pressure ulcers; chronic vascular ulcers; diabetic ulcers; tunneled, undermined wounds; trauma wounds; drainage wounds; and surgical wounds.

Field of Use
Field of Use means acellular extracellular matrix products derived from perfusion decellularization but excluding (i) decellularized Whole Organs; (ii) all non-clinical applications; and (iii) use in three-dimensional printing applications including but not limited to mapping associated therewith. For the avoidance of doubt, under no circumstances does the Field of Use include the addition of cells to the extracellular matrix.

IPSCIO Record ID: 26542

License Grant
The Licensor granted the Licensee a non-exclusive License under the Licensed Patents to make, have made, use, import, sell, promote, market, offer for sale or otherwise transfer royalty-Bearing Products in the Licensed Fields throughout the world. This grant includes the right for the Licensee to grant subLicenses to this Agreement without payment of any additional royalty to the Licensor.
License Property
5,165,938 entitled 'Wound Healing Agents,' issued 11/24/92

Schedule of Disposable Products

Model Number Description UOM
7117-8200 Disposable Platelet Concentrator
(Market Evaluation Unit) One (1)
7117 8202  Disposable Platelet Concentrator One (1)
7117-8201 Graft Delivery System One (1)
7117-8203 Spray Applicator One (1)
7117-8204 Dual Lumen Applicator One (1)

Field of Use
“Licensed Fields” means all applications except use in treatment of diabetic foot ulcers, pressure ulcers, venous stasis and other wounds treated outside of surgery.

IPSCIO Record ID: 309459

License Grant
By the initial agreement Licensor grants to Licensee, its subsidiary, certain rights to Licensor’s technologies in the field of human Wound Care.  The original license was exclusive.

The parties now hereby agree to amend, modify and supplement the License Agreement as follows in order to include additional products developed by Licensee
–  the definition of Field of Use in the License Agreement,
–  the definition of Wound Care in the License Agreement.

License Property
Licensee has developed a product called Clyraguard, a derivative of the licensed technologies, that it believes could fulfill a pivotal role in the COVID-19 pandemic, and desires to manufacture, market and sell that product.

Additionally, the License Agreement contemplates thirteen expanded Fields of Use,  which include oral/dental/periodontics mouthwash and rinse, hydration for patients, and Licensee has developed such a product (OraClyr), and therefore desires to further expand the License to include such product.

As of this amendment, Wound Care means articles, compositions, and methods for medical treatment to treat a condition comprising damage to a human patient, the condition including substantive traumatic or non-traumatic breach of the derma. Such medical treatment may include extended application of an article of manufacture (wraps, bandages, bandaids and appliqués) over the epidermis, or wipes or direct application of medication such as liquid, ointment, spray, cream or paste, including any chemistry used on or in a patient during surgery. As non-limiting examples of traumatic damage are cuts, scrapes, punctures, incisions and other intentional or accidental penetration damage through the epidermis. As non-limiting examples of non-traumatic damage are treatment, prophylaxis or prevention of sores, topical infections, insect bites, sub-epidermal infections, boils, and lesions (in the absence of a previous wound at the site). Wound Care includes surgical damage to tissues and organs during surgical or other medical procedures as well as from accidental damage to tissues and organs. Surgical and medical procedures, and traumatic events, also include care of the mouth, gums, eyes, optical system and all other organs and tissues. Wound Care does NOT include products intended for the treatment of animals.

As of this amendment, Licensed Processes means any method, process, modality, procedure, practice, or course of action within the Field of Use covered by a claim of Patent Rights, and/or that incorporates or includes know-how, trade secret, or proprietary information of Licensor.

As of this amendment, Licensed Products means any means any article, kit, equipment, system, method, apparatus or unit within the Field of Use covered by a claim of Patent Rights and/or that incorporates or includes know-how, trade secret, or proprietary information of Licensor.

Licensors business objective is to harness and deliver nature’s best disinfectant – iodine – in a safe, efficient, environmentally sensitive and cost-effective manner. The core of this innovative technology is the accurate and safe delivery of iodine in a wide range of forms, moieties and conditions.

Field of Use
Clyraguard is a personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of COVID-19 disease.

The Licensee has received test results showing that its proprietary copper iodine antimicrobial and antiviral product, Clyraguardâ„¢, successfully inactivated the COVID-19 coronavirus (SARS-CoV-2 virus), the virus responsible for the current worldwide pandemic.

Licensee was formed by Licensor to commercialize our technology in the medical products industry, with an initial focus on advanced wound care.

As of this agreement, Field of Use means prescription-based and over-the-counter products in
(i) the commercial field of human Wound Care in the medical, dental and ophthalmologic fields of prescription-based; and
(ii)  the commercial field of oral, dental, and periodontis, including mouthwash and rinse, and hydration for patients.

(iii)  Field of Use does NOT include products or processes intended for use on surfaces (e.g., disinfection of a hospital floor or other a hard surface) or other devices usable in a medical setting (e.g., disinfection of a metal instrument used to treat a patient). Field of Use does NOT include over-the-counter products available without a prescription.

IPSCIO Record ID: 26365

License Grant
The Licensee entered into an agreement with a national blood bank, under which the blood bank supplies the blood that serves as the raw material for, and manufactures, the Licensee's CureXcell product in Israel. Under the agreement, the blood bank produces CureXcell based on the Licensed Technology and based on the Licensee’s needs.
License Property
CureXcell is an injectable suspension of living human white blood cells, including macrophages, neutrophils and lymphocytes, that are crucial to initiating, promoting and completing the process of cellular regeneration and wound healing. The Licensee uses proprietary cell activation technology to trigger these cells to release growth factors and other biochemical factors that improve the healing environment in the wound bed and stimulate wound closure.
Field of Use
The CureXcell product is sold to health care professionals in Israel for clinical purposes as part of the Licensee’s research and development activities. The Licensee is a regenerative medicine company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds. Their product candidate, CureXcell, is an advanced wound care, or AWC, therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process. CureXcell is currently in two pivotal, Phase 3, double-blind clinical trials targeting a broad indication for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. The Licensee anticipates results from their DFU clinical trial and interim data from their VLU clinical trial in the second half of 2015. They already hold product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds, and have effectively and safely treated more than 5,000 patients in commercial or clinical study settings in Israel.

IPSCIO Record ID: 256319

License Grant
The University grants a worldwide right and license to make, have made, use, lease, sell, and sublicense the Pre-issuance Products and Licensed Products under the Patent Rights, and to practice and sublicense the Pre-issuance Processes and Licensed Processes to the full end of the term(s) for which Patent Rights are granted unless sooner terminated as hereinafter provided.
License Property
The Invention will mean a wound treatment technology, Method and Apparatus to Enhance Closure and Health of Open Wounds.

The patents are Wound Dressing and Treatment Method, Fluidic Connection System and Method, and, Fastening System and Method.

Field of Use
Licensee is a global medical technology company in advanced wound care and therapeutic surfaces.

IPSCIO Record ID: 324660

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, on and subject to the terms and conditions hereinafter set forth, the exclusive right to distribute Products throughout the territory solely for use in the field. Licensee shall not sell, or sell to others that it has reason to believe will resell, any Products outside the territory or for use outside the field.

Licensor hereby acknowledges that a reliable and continuous source of supply of Products is imperative to Licensees successful marketing efforts. Therefore, as a material inducement to the execution of this Agreement by Licensee, Licensor hereby grants to Licensee a current license and sublicense of its rights under the License Agreement (in each case without the right to sublicense) under existing and proprietary rights to manufacture, have manufactured, use and sell Products in the field throughout the territory, subject to the terms hereof. Licensee agrees, however, to withhold the exercise of its rights for each product under this current license until the happening of any one or more of the following events with respect to the product Licensor becomes insolvent; Licensor has ceased manufacturing the product;  Licensor fails to deliver to Licensee all quantities of product ordered in accordance with this Agreement for delivery in a calendar quarter.

Licensor grants to Licensee and its affiliates a royalty-free license to utilize the Trademarks in the field throughout the territory on and in connection with the promotion of the Products provided by Licensor hereunder and, with respect to Products resulting from the exercise of Licensees license rights in this agreement.

License Property
US Patent 4,760,051 – Use of GHL-Cu as a wound-healing and anti-inflammatory agent
US Patent 4,810,693 – Method for inducing biological coverings in wounds
US Patent 4,937,230 – Method of healing wounds in horses

Products – shall mean the Products manufactured by Licensor for and on behalf of Licensee under this Agreement, as more fully described in this agreement hereto and incorporated herein, together with any and all improvements thereof that are manufactured by Licensor for sale in the territory for use in the field. This list may be amended from time to time upon mutual agreement of the parties.
Iamin® Hydrating Gel
Iamin® Wound Cleanser
OsmoCyte® Pillow Wound _Dressing
ProCyte Transparent Film Dressing
OsmoCyte® PCA Pillow ·wound Dressing
Iamin® Hydrating Gel II
OsmoCyte® Island Dressing

Proprietary Rights – shall mean all know-how, trade secrets and patent rights (including process patents)  owned by or licensed to Licensor which are required in order to manufacture the Product to applicable specification in the territory, including without limitation the patent and patent applications described hereto and incorporated herein; provided, however, that for purposes of Article XI, proprietary rights shall not include those proprietary rights currently licensed to, or hereafter owned by or licensed to, Licensor unless (i) Licensee agrees, upon thirty (30) days notice, to pay and does pay promptly all royalties and other amounts due the licensor (in addition to the amounts set forth in Article XI) and to perform and be bound by all obligations due the licensor and (ii) Licensor has the right to grant licenses or sublicenses with respect thereto. Licensor shall use its good faith efforts to include in any such agreement the right to grant such licenses or sublicenses.

Trademarks – shall mean the trademarks listed
Iamin (U.S. Registration Only)
OsmoCyte (U.S. Registration Only)

Field of Use
Field – shall mean the sub-field of medicine relating to the treatment of human acute and chronic wounds and skin irritations in hospitals, health care facilities, nursing homes and extended care facilities, excluding wounds and skin irritations related to plastic/cosmetic surgery and hair transplantation.

IPSCIO Record ID: 383121

License Grant
Buyer will purchase all wholly owned Sellers assets related to wound-care which are  Amniobind, next generation Amniobind, and injectable regenerative medicine products only to the extent these are indicated for wound care; as well as wholly owned Seller IP, IT and equipment for producing Amniobind and next generation Amniobind and injectable regenerative medicine products only to the extent these are indicated for wound care – (collectively the Wound Care Assets).  

Buyer will non-exclusively license, sublicense, lease, or sublease equipment that is not owned by Seller but is used for the production of Wound Care Assets.

Field of Use
Field of use is for wound-care.

IPSCIO Record ID: 3180

License Grant
In this agreement, the Licensor established a joint venture company with a German Company, the entity is the Licensee.

The Licensor has granted the Licensee global distribution rights in this regard.

This new enterprise is charged with obtaining the CE mark certification authorizing the distribution of the Hemospray wound spray in the member states of the European Union.

License Property
Hemospray Wound Spray

The Licensor has developed a novel medical product aimed at the healing of chronic wounds. Chronic wounds are a medical problem of increasing importance as they originate from widespread risk factors such as diabetes, obesity, smoking etc. Lack of oxygen supply to the cells in the wound ground is the main reason why those wounds lose their genuine healing power. Based on its concept of artificial oxygen carriers, our Hemospray wound spray product bridges the watery wound surface and permits an enhanced afflux of oxygen to the wound ground.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.